What is the current price of a box of dacomitinib/dacomitinib?

Dacomitinib/Dacomitinib (Dacomitinib) is a targeted anti-cancer drug mainly used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body. As an oral tyrosine kinase inhibitor, dacomitinib effectively prevents the proliferation and metastasis of tumor cells by targeting the EGFR (epidermal growth factor receptor) signaling pathway. For those patients with EGFR mutations, dacomitinib provides a new treatment option, especially in first-line treatment, showing good efficacy.

In China, dacomitinib has been approved and marketed, and is listed as a Class B medical insurance drug, which provides many patients with more affordable treatment opportunities. Patients can purchase the original drug directly in hospitals or pharmacies. Usually a box of 15 mg dacomitinib contains 30 tablets, and the market price is about 1,000 yuan. This price is more acceptable than other targeted drugs, making this effective treatment affordable for more patients.

However, for patients overseas, the price of dacomitinib is relatively expensive. For example, in some European countries, the price of 45mg dacomitinib may be as high as more than 20,000 yuan. This not only increases the financial burden on patients, but also price fluctuations are affected by exchange rate changes, putting patients under greater financial pressure.

Fortunately, overseas markets also provide more affordable generic options for dacomitinib. For example, a dacomitinib generic drug produced in Laos has a specification of 45mg*30 tablets and costs only about 800 yuan. Although the price will also change with exchange rate fluctuations, its price advantage is obvious compared to the original drug. This gives patients more choices when seeking treatment and reduces the financial burden of treatment.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro